 |
 |
 |
 |
 |
 |
 |
 |
 |
"In May 2003, Easton led a $55.3 million financing for Acorda Therapeutics,
one of the top three private biotechnology financings to date in 2003. Easton's ability to lead
such a significant round, particularly in a challenging financial environment, is a testament to
its capabilities and excellence. Acorda's management and Board were thoroughly impressed by the
acumen and performance of the people at Easton. They comprise a rare mix of expertise in finance,
life sciences, business development and value creation, together with meticulous attention to detail
and passionate commitment. We are especially pleased that John Friedman has joined our Board of
Directors, where we expect his insights to contribute substantially to Acorda's future successes."
Ron Cohen
Founder, President, and CEO, Acorda Therapeutics
Acorda Therapeutics, Inc.
(NASD:ACOR) is a biotechnology company developing therapies for multiple sclerosis and related neurological conditions such as spinal cord injury (SCI). Acorda had a successful initial public offering in February 2006.